Ask about this productRelated genes to: Psenen antibody
- Gene:
- PSENEN NIH gene
- Name:
- presenilin enhancer, gamma-secretase subunit
- Previous symbol:
- -
- Synonyms:
- PEN2
- Chromosome:
- 19q13.12
- Locus Type:
- gene with protein product
- Date approved:
- 2005-02-08
- Date modifiied:
- 2019-04-23
Related products to: Psenen antibody
Related articles to: Psenen antibody
- The identification of reliable biomarkers for prostate cancer remains a pressing need in clinical oncology. Inflammatory and regulatory molecules such as NF-κB p65, apolipoprotein E (ApoE), angiopoietin-1 (Ang-1), forkhead box protein A2 (FOXA2), presenilin enhancer-2 (PEN-2) and β-amyloid precursor protein (β-APP) have been implicated in tumour biology. However, their roles in prostate cancer progression and invasion require further elucidation. - Source: PubMed
Albaz Ali CanKosova FundaTemeltaş GökhanÜçer OktayMüezzinoğlu Talha - Lung cancer remains a leading cause of cancer-related mortality worldwide. Chemotherapy, including cisplatin, plays a pivotal role in its treatment; however, the development of cisplatin resistance presents a major clinical challenge. The PSENEN gene, which encodes a regulatory protein, is overexpressed in numerous malignancies. This study explores the role of PSENEN in mediating cisplatin resistance in non-small cell lung cancer (NSCLC). RNA sequencing revealed significant upregulation of PSENEN in cisplatin-resistant A549/DDP cells. Functionally, PSENEN inhibition reversed cisplatin resistance, inhibited cell proliferation and metastasis, and enhanced programmed cell death in A549/DDP cells. Single-cell RNA sequencing indicated that PSENEN was expressed in both cancer and stromal cells. Further functional studies suggested that PSENEN regulates chemoresistance through interactions within the stromal microenvironment. Differentially expressed protein analysis (DIA) of stromal cell supernatants, coupled with functional assays, identified PPIB as a key mediator of PSENEN's effect on lung cancer cell drug resistance via stromal signaling. In vivo, pharmacological inhibition of PSENEN significantly suppressed subcutaneous tumor growth. Additionally, analysis of the immune microenvironment revealed a strong correlation between PSENEN expression and the infiltration of multiple immune cell types. Multiple immunofluorescence and immunohistochemistry validation confirmed that PSENEN is positively correlated with CD56 and PD-1, suggesting its potential application value in immunotherapy. - Source: PubMed
Publication date: 2025/12/16
Cao ZhenyuZhu JiaqiQin ZheChen ZhijianWu TongLin WenxiGao BoGu HaoyiJiang YunChen Jianle - To assess the potential therapeutic effects of glucose-dependent insulinotropic peptide (GIP) on hyperandrogenism. - Source: PubMed
Publication date: 2025/11/17
Pan MengruQian YifanJiang LinlinCao ChunweiLi Lin - Endometrial cancer (EC) is a prevalent gynecological malignancy with increasing incidence worldwide. Despite advancements in treatment, challenges such as tumor recurrence and chemoresistance persist. Acrylamide, a probable carcinogen formed in high-temperature cooked foods, has been associated with EC risk, but its oncogenic mechanisms remain underexplored. - Source: PubMed
Publication date: 2025/10/02
Zou YitingLu ShanHan ShiqiangZhao Renfeng - Regulatory T cells (Tregs) have multiple roles in the tumor microenvironment (TME), which maintain a balance between autoimmunity and immunosuppression. This research aimed to investigate the interaction between cancer stemness and Regulatory T cells (Tregs) in the breast cancer tumor immune microenvironment. Breast cancer stemness was calculated using one-class logistic regression. Twelve main cell clusters were identified, and the subsequent three subsets of Regulatory T cells with different differentiation states were identified as being closely related to immune regulation and metabolic pathways. A prognostic risk model including , , , , , , and was generated through the intersection between Regulatory T cell differentiation-related genes and stemness-related genes using LASSO and univariate Cox regression. The patient's total survival times were predicted and validated with AUC of 0.96 and 0.831 in both training and validation sets, respectively; the immunotherapeutic predication efficacy of prognostic signature was confirmed in four ICI RNA-Seq cohorts. Seven drugs, including Ethinyl Estradiol, Epigallocatechin gallate, Cyclosporine, Gentamicin, Doxorubicin, Ivermectin, and Dronabinol for prognostic signature, were screened through molecular docking and found a synergistic effect among drugs with deep learning. Our prognostic signature potentially paves the way for overcoming immune resistance, and blocking the interaction between cancer stemness and Tregs may be a new approach in the treatment of breast cancer. - Source: PubMed
Publication date: 2025/07/21
Gul SaminaPang JianyuChen YongzhiQi QiTang YuhengSun YingjieWang HuiTang WenruZhou Xuhong